Episode Details
Back to Episodes80. Viloxazine (Qelbree) or Atomoxetine (Strattera) for ADHD: Which should you choose?
Description
Dr. Elise Fallucco continues this series on non-stimulant medication for ADHD and shares practical tips about using Norepinephrine Reuptake Inhibitors (NRIs): viloxazine ER (Qelbree) and atomoxetine (Strattera) for pediatric clinicians.
Who can benefit from NRIs? What are the potential benefits, drawbacks, and side effects?
Working through the case of a 12-year-old girl with inattentive ADHD and anxiety who cannot tolerate methylphenidate or amphetamine , she explains why she generally prefers Viloxazine ER (Qelbree)
- FDA approval for ADHD in children ages 6+
- Quicker onset (often within 1–2 weeks vs 4–6 weeks for atomoxetine)
- Better tolerability
- More straightforward dosing
- Unlike Atomoxetine (Strattera), you can dose this medication without worrying about significant genetic variability in drug metabolism
00:00 NRIs for ADHD
00:38 When to Use
01:07 Case Introduction
02:51 Stimulant Trials Fail
04:09 Considering NRIs
04:30 Why Qelbree First
05:51 Atomoxetine Caveats
07:23 Treating Sophie
08:45 Clinical Pearls Recap
09:50 Wrap Up and CME
Sign-up for our NEWSLETTER
Check out PsychEd4Peds.com for more resources!
SOCIAL @psyched4peds
On-demand CME Course online at: Pediatric Mental Health CME Toolkit - Cracking the ADHD Code: Essentials for Pediatric Clinicians.